In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on MEI Pharma (MEIP). The company’s shares opened today at $3.01.
According to TipRanks.com, Gershell is a 2-star analyst with an average return of 0.0% and a 43.8% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Anchiano Therapeutics Ltd, Avenue Therapeutics Inc, and Evofem Biosciences Inc.
MEI Pharma has an analyst consensus of Strong Buy, with a price target consensus of $7.75.
See today’s analyst top recommended stocks >>
The company has a one-year high of $5.14 and a one-year low of $1.82. Currently, MEI Pharma has an average volume of 229.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MEI Pharma, Inc. engages in the clinical development of novel therapies for cancer. Its drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
